Form 4: HCW Biologics Director Scott T. Garrett Acquires Stock Options
SEC Form 4 Filing
Director Scott T. Garrett acquired stock options in HCW Biologics Inc. on June 14, 2024.
Summary
- On June 14, 2024, Scott T. Garrett, a director of HCW Biologics Inc., acquired stock options.
- The options grant the right to buy 12,500 shares of common stock at an exercise price of $1.12.
- The options vest on the earlier of June 13, 2025, or the next annual meeting of stockholders, contingent upon continued service.
- Following the transaction, Garrett directly owns 12,500 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a stock option grant, which is neutral in sentiment. It doesn't inherently indicate positive or negative performance.
Positives
- The acquisition of stock options by a director may signal confidence in the company's future performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, providing investors with insights into the actions of company insiders.
Stakeholder Impact
- The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/14/2024 | Date of the stock option transaction. |
| 06/13/2025 | First possible vesting date for the stock options. |
| 06/13/2034 | Expiration date of the stock options. |
| 06/17/2024 | Date of the form filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.